Mubadala Healthcare

What Mubadala Healthcare does

Mubadala Healthcare is the healthcare-focused investment platform of Mubadala Investment Company, an Abu Dhabi-based sovereign investor wholly owned by the Government of Abu Dhabi. The platform invests across life sciences, biopharmaceutical manufacturing, digital health, and healthcare services globally, with the stated mandate of helping to address the region's most pressing healthcare needs through a network of specialist holdings and partnerships.

The healthcare portfolio spans direct equity investments, wholly-owned subsidiaries, and joint ventures. Anchor holdings include Mubadala Bio—a national life sciences champion launched in 2025 with 10 global biopharma manufacturing facilities and local production of eight essential medicines—alongside significant stakes in PCI Pharma Services (biologics and specialized drug manufacturing, with a re-investment in July 2025 after a 2020 entry), WHOOP (US$75 million committed in 2026 to establish the company's regional headquarters in the UAE alongside participation in its US$575 million Series G at a US$10.1 billion valuation), and historical investments in Envirotainer, Evotec, and Norstella. The healthcare vertical is led from within the Private Equity platform by Co-CEO Camilla Languille, who previously served as Head of Healthcare and holds board seats at PCI Pharma Services and Evotec.

Mubadala's underlying business model centers on deploying long-term sovereign capital across asset classes to generate risk-adjusted returns for its sole shareholder while advancing the UAE's economic diversification agenda away from oil dependency. The firm operates four business platforms—Private Equity, UAE Investments, Credit and Special Situations, and Real Assets—supported by Mubadala Capital, an alternative asset management subsidiary that manages, advises, and administers over US$430 billion in assets and serves global institutional limited partners. The go-to-market is sales-led and relationship-driven, with capital distributed through direct private market investments, co-investments with global partners (KKR, Apollo, Stonepeak, Bain Capital, Cinven, Fortress, Barings, Ardian, and others), and structured fund vehicles such as the Mubadala Capital Co-Investment Fund I. Healthcare represents a strategic vertical within this broader mandate rather than a standalone operating company, and the firm reports multi-year performance metrics—5-year IRR of 10.7% and 10-year IRR of 10.3%—rather than annual revenue or net income.

Name

Mubadala Healthcare

Legal name

Mubadala Investment Company

Website

https://mubadala.com

Company type

Private

Founded year

1984

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Mubadala Healthcare is the healthcare investment platform of Mubadala Investment Company, an Abu Dhabi sovereign investor. It deploys capital across biopharma, digital health, and life sciences via direct investments, joint ventures, and its Mubadala Bio subsidiary.

Ownership category

akta.pro rank

Product category

Healthcare Investment Management

NAICS

General Medical and Surgical Hospitals (6221), General Medical and Surgical Hospitals (622110), General Medical and Surgical Hospitals (62211)

SIC

Services-General Medical & Surgical Hospitals, Nec (8062), Services-Hospitals (8060), Services-Health Services (8000)

akta.pro primary industry

Community & Regional General Hospitals (HLAFAAAB)

Keywords

• Healthcare investment
• Biopharmaceutical manufacturing
• Life sciences platform
• Specialty healthcare services
• Sovereign healthcare assets

Headquarters

HQ city

Abu Dhabi

HQ country

United Arab Emirates

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Investment Returns: Mubadala generates returns through capital gains, dividends, and interest income from its diversified portfolio of direct investments, public market holdings, and alternative assets.
2. Asset Management (Mubadala Capital): Mubadala Capital, the alternative asset management subsidiary, manages over $430 billion in assets through asset managers and strategic partnerships, generating management fees and performance fees.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Mubadala Healthcare addresses the region's most pressing healthcare needs through a network of specialist healthcare providers, life sciences assets, and biopharmaceutical manufacturing. The platform deploys capital across growth-oriented healthcare and life sciences companies globally while building national champions (such as Mubadala Bio with 10 global facilities) to strengthen the UAE's healthcare and biopharma capabilities.

Product overview

Mubadala Investment Company is a sovereign investor managing a diverse portfolio of assets through multiple investment platforms and subsidiaries. The company operates through Private Equity, UAE Investments, Credit and Special Situations, and Real Assets platforms, along with Mubadala Capital (its alternative asset management subsidiary managing over $430 billion). Key portfolio companies include Mubadala Bio (life sciences), various energy and infrastructure investments, and financial services holdings. Mubadala does not offer a unified product platform; rather, it manages investments across portfolio companies with varying product and service offerings.

Differentiator

Problem solved

Functional benefit

Products and services

• Mubadala Bio
• Mubadala Capital (with Healthcare investment focus)
• Mubadala Capital Co-Investment Fund I (MCCF)

Quantifiable outcome

• 17% year-over-year AUM growth to AED 1.4 trillion (US$385 billion)
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• WHOOPcoreStrategic or Co-development Partner · 7 May 2026$75 million investment from Mubadala to establish WHOOP's regional headquarters in UAE, launch Advanced Labs, Arabic digital services, and joint research initiative for preventative health. WHOOP is a human performance company with 2.5 million members.
• TubacexcoreStrategic or Co-development Partner · 4 May 2026Launch of TBX Nexxia in Abu Dhabi as end-to-end CRA OCTG platform with $200 million investment, operational capacity of 20,000 tons annually, serving ADNOC's long-term pipe supply requirements.
• Aldar PropertiescoreStrategic or Co-development Partner · 21 April 2026Joint venture between Aldar and Mubadala acquired The Link at Masdar City for AED 654 million. The fully leased mixed-use development spans 32,000 sqm across five buildings, anchored by Masdar and MBZUAI.
• Mayo CliniccoreStrategic or Co-development Partner · 31 March 2026Mayo Clinic participated in WHOOP's Series G funding round, bringing clinical and research expertise to support personalized health platform development.
• EquitixcoreStrategic or Co-development Partner · 1 January 2025Mubadala invested $200 million to acquire a stake in Greenlink, a joint venture between Equitix and Baltic Cable, operating a 504 MW electricity interconnector between Great Britain and Ireland. The project is a high-voltage subsea interconnect that strengthens energy interconnection and supports renewable integration.
• Fortress Investment GroupcoreStrategic or Co-development Partner · 1 January 2025Strategic partnership focused on credit and special situations seeking to deploy US$1 billion from Mubadala across Fortress's private credit, asset-based lending, and real estate strategies.
• BaringscoreStrategic or Co-development Partner · 1 January 2025US$500 million global real estate debt partnership combining Barings' real estate debt expertise with Mubadala's global investment platform for innovative credit solutions across US, Europe, and Asia-Pacific.
• HayfinminorStrategic or Co-development Partner · 1 January 2025Strategic partnership with AXA IM Prime and Hayfin to acquire minority interest from Arctos Partners in Hayfin.
• CorientcoreStrategic or Co-development Partner · 1 January 2025Partnership through Mubadala Capital advancing consolidation strategy with acquisitions of Stonehage Fleming and Stanhope Capital Group, bringing over US$214 billion in client assets.
• ArdiancoreStrategic or Co-development Partner · 1 January 2025Multiple partnerships including investment in Kering retail properties in Paris and New York for US$253 million, and infrastructure secondaries investment program.

Scale indicators9 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• NMC Healthcare: UAE-headquartered private hospital and healthcare operator with a multi-specialty hospital network across the Emirates — directly comparable regional healthcare delivery footprint.
• Burjeel Holdings: Abu Dhabi-based integrated healthcare provider operating hospitals and specialized medical centers in the UAE — the closest regional peer in terms of geography and multi-specialty hospital operations.
• Abu Dhabi Investment Authority (ADIA): Sovereign investor and Mubadala's Abu Dhabi peer, deploying capital globally including healthcare — directly comparable as a state-owned investment vehicle with similar mandate and return horizon.
• VPS Healthcare: UAE-headquartered healthcare conglomerate operating hospitals, clinics, and pharmaceutical manufacturing across the Middle East, India, and Europe — comparable in scope of integrated healthcare services.
• Aster DM Healthcare: One of the largest integrated healthcare operators in the GCC and India, headquartered in the UAE, operating hospitals, clinics, and pharmacies across the same regional footprint as Mubadala Healthcare.
• Kuwait Investment Authority (KIA): Gulf sovereign wealth fund and Mubadala's regional peer, investing globally across asset classes including healthcare — comparable institutional mandate and shareholder structure.
• Mediclinic International: International hospital group with substantial UAE/MENA operations through Mediclinic Middle East, operating multi-specialty acute care hospitals comparable to Mubadala Healthcare's network.

Regional players

• Saudi German Hospitals Group: One of the largest private hospital operators in the MENA region, headquartered in Saudi Arabia with comparable GCC healthcare delivery scale — overlapping market but different primary geography.

Broad incumbents

• Public Investment Fund (PIF): Saudi Arabia's sovereign wealth fund with healthcare strategies including local pharmaceutical manufacturing and health sector investments under Saudi Vision 2030 — comparable regional sovereign healthcare mandate.
• Temasek Holdings: Singapore sovereign investor with a substantial healthcare and life sciences portfolio including biopharma and healthcare delivery — analogous institutional investor with global healthcare exposure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/Mubadala
• YouTubeyoutube.com/user/mubadalauae
• Facebookfacebook.com/Mubadala
• LinkedInlinkedin.com/company/55857
• Instagraminstagram.com/mubadala

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mubadala Healthcare